TERBUNY, RUSSIA--(Marketwired - July 17, 2013) - The pharmaceutical plant operations of Rafarma Pharmaceuticals, Inc. (OTC: RAFA) are run by its operational subsidiary, "ZAO Rafarma." Day-to-day production activities, as well as operational and business expansion, are led by a well-qualified team of pharmaceutical and business professionals. A new Board of Directors for ZAO Rafarma was recently elected and includes the following industry veterans:
Nadezhda Brusnitsina, Chairman of the Board - Former director of the MBA program for the Russian Academy of National Economy and State Service, under the President of the Russian Federation, where she was also a Professor in the Department of Project Management. Ms. Brusnitsina has a PhD in Economics and over 13 years' experience in management.
Irina Shashkova, First Deputy to Director-General - With more than 30 years experience in various pharmaceutical enterprises, Ms. Shashkova provides a broad range of skills in the industry. She was awarded a certificate of excellence by the Ministry of Health of Russian Federation for her work in advancing pharmaceutical initiatives in Russia.
Andrey Sinitsin, M.D. - Dr. Sinitsin is a medical professional with over 10 years experience in marketing and sales of pharmaceutical products. Mr. Sinitsin has been a key contributor in growing Rafarma, particularly in the procurement of production contracts for the company.
Mikhail Nazarychev - Mr. Nazarychev's experience and skill set are in investment and commercial banking. Mr. Nazarychev obtained his educational degrees at the Russian Federation Finance Academy where he majored in banking and finance. Mr. Nazarychev has played a key role in the financing of the company's growth and expansion.
Tatiana Leontieva, J.D. - A graduate of Moscow University in Social law, Ms. Leontieva is a seasoned corporate professional who also has held important government positions for the Russian Federation. Ms. Leontieva was part of the team that initiated and founded ZAO Rafarma. She also holds board positions, including a chairmanship, with industry-related companies.
Hartmut Gerlof - Vice President of Textima, Germany. Mr. Gerlof brings to Rafarma a lengthy history of corporate management of large companies within the industry. Mr. Gerlof's experience allows him to facilitate relations with the German Science and Manufacturing communities for the expansion of Rafarma's revenue opportunities in Germany.
Professor Dr. Hartwig Steckel - Dr. Steckel is a licensed pharmacist as well as the Director of the Department of Pharmaceutics and Biopharmaceutics (Institute of Pharmacy) at Christian Albrecht University in Kiel, Germany. Dr. Steckel is also a member of the International Association for Pharmaceutical Technology (APV), the American Association for Pharmaceutical Scientists (AAPS) and the German Pharmaceutical Society (DPhG).
CEO Dave Anderson stated: "We welcome these new members and look forward to working closely with such a diverse and experienced board."
About Rafarma Pharmaceuticals, Inc.
Operating from a new 270,000 square-foot state-of-the-art manufacturing and distribution facility in Russia, Rafarma Pharmaceuticals produces generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. For the last three years, the Russian Government has been highly focused on bolstering the development of nation's domestic pharmaceutical industry. Rafarma Pharmaceuticals' mission is to work with the auspices of aggressive federal initiatives to fast-track the modernization of Russia's pharmaceutical industry.
For more information on Rafarma Pharmaceuticals, visit: http://RAFA.QualityStocks.net
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.